Top Suppliers:I want be here

  • DC Chemicals Limited
  • China
  • Product Name: Ablukast
  • Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

96566-25-5

96566-25-5 structure
96566-25-5 structure
  • Name: Ablukast
  • Chemical Name: 6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-chromene-2-carboxylic acid
  • CAS Number: 96566-25-5
  • Molecular Formula: C28H34O8
  • Molecular Weight: 498.56500
  • Catalog: Signaling Pathways GPCR/G Protein Leukotriene Receptor
  • Create Date: 2018-02-20 08:00:00
  • Modify Date: 2024-01-03 10:41:55
  • Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction[1][2]. Ablukast is LTD4 receptor antagonist[3].

Name 6-acetyl-7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentoxy]-3,4-dihydro-2H-chromene-2-carboxylic acid
Synonyms rac-6-acetyl-7-<<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl>oxy>-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid
Ablukast
4-dihydro-2H-1-benzopyran-2-carboxylic acid
Ablukastum
7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)-pentyloxy]-6-acetyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid
6-acetyl-7-<5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyloxy>-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid
UNII-000TKM5BBQ
Ro-23-3544
Ablukast (USAN/INN)
Ablukastum [INN-Latin]
7-[5-(4-acetyl-3-hydroxy-2-propylphenoxy)-pentyloxy]-6-acetyl-3
Description Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction[1][2]. Ablukast is LTD4 receptor antagonist[3].
Related Catalog
Target

LTD4

In Vitro Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation[2].
In Vivo Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation[2]. Animal Model: Female BALB/c mice[2] Dosage: Concentrations of 0.1 , 0.5 , 1.0 and 5.0 % of Ablukast Administration: Applied to one of the pretreated ears 1 h after elicitation and at 24 h intervals on the following 4 days; three times daily Result: Effectively reduced DNFB-induced ear swelling.
References

[1]. M O'Donnell, et al. Pharmacological profile of Ro 23-3544, a new aerosol active leukotriene receptor antagonist. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:512-8.

[2]. T Rosenbach, et al. Studies on the role of leukotrienes in murine allergic and irritant contact dermatitis. Br J Dermatol. 1988 Jan;118(1):1-6.

[3]. Hans-Michael Eggenweiler, et al. Pyrrolopyrimidines as phosphodiesterase VII inhibitors. US7498334B2.

Density 1.219g/cm3
Boiling Point 730.8ºC at 760mmHg
Molecular Formula C28H34O8
Molecular Weight 498.56500
Flash Point 240.9ºC
Exact Mass 498.22500
PSA 119.36000
LogP 5.15620
Index of Refraction 1.567